中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 6
Jun.  2012
Turn off MathJax
Article Contents

Analysis of clinical characteristics of the infection of HCV genotype 1 and non-genotype 1 in China

Research funding:

 

  • Published Date: 2012-06-20
  • Objective To clear preliminary clinical characteristics of the infection of HCV genotype 1 and non-genotype 1 in China.Methods Through a national multi-center, large sample epidemiological survey, certified by an international third-party testing organization qualifications, using the internationally accepted method for sequencing analysis of viral genotype, and further on the clinical characteristics of the infection of HCV genotype 1 and non-genotype 1 were analyzed.Results Plasma samples of 764 patients from 18 research centers of China were collected.384 patients were maleand 380 were female, and the mean age was 44.9 ± 14.3 years, the mean duration was 7.7 ± 7.3 years.By analyzing the clinical features, we found that, in the age distribution and duration of disease, the genotype 1 virus infected patients have a greater age and longer duration than that in non-genotype 1 infected patients.The comparison of the ALT levels in patients with a cross-sectional survey showed that 54.9% with abnormal ALT in genotype 1 patients, and 56.9% in non-genotype 1 patients, There was no significant difference (P>0.05) .The comparison of BMI levels in patients showed that abnormal BMI was 39.6% of the patients infected with genotype 1 HCV and 39.6% non-genotype 1.There was no significant difference (P>0.05) .We divided the routes of infection into the blood transfusion infection and Non-transfusion routes of infection.In the patients with blood transfusion infection, 66.1% were genotype 1, while in the patients with non-infected blood transfusion, non-genotype 1 infection accounted for 51.1%.There was a significant difference (P<0.05) .Conclusion Compared with HCV non-genotype 1, HCV genotype 1 infected patients have greater age distribution and longer duration, mostly of them were blood transfusions.

     

  • loading
  • [1] 中华医学会肝病学分会、传染病与寄生虫病学分会.丙型肝炎防治指南[J].中华肝脏病杂志, 2004, 12 (4) :194-198.
    [2]Strader DB, Wright T, Thomas DL, et al.American association forthe study of liver diseases[J].Hepatology, 2001, 34 (4) :A2-A5.
    [3]Schinazi RF, Sommadossi JP, Thomas HC.Epidemiology, natural his-tory∥Therapies for viral hepatitis[C].RF:international medicalpress, 1998.
    [4]Firpi RJ, Clark V, Soldevila-Pico C, et al.The natural history ofhepatitis C cirrhosis after liver transplantation[J].Liver Transpl, 2009, 15 (9) :1063-1071.
    [5]Dieterich DT, Rizzetto M, Manns MP.Management of chronic hep-atitis C patients who have relapsed or not responded to pegylated in-terferon alfa plus ribavirin[J].J Viral Hepat, 2009, 16 (12) :833-843.
    [6]Orlent H, Vrolijk JM, Veldt BJ, et al.Hepatitis C 2002 guide-lines:summary and annotations[J].Scand J Gastroenterol Suppl, 2003, (239) :105-110.
    [7]Fried MW, Shiffman ML, Reddy KR, et al.Peginterferon alfa-2aplus ribavirin for chronic hepatitis C virus infection[J].N Engl JMed, 2002, 347 (13) :975-982.
    [8]Manns MP, Mchutchison JG, Gordon SC, et al.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirinfor initial treatment of chronic hepatitis C:a randomised trial[J].Lancet, 2001, 358 (9286) :958-965.
    [9]Zeuzem S, Pawlotsky JM, Lukasiewicz E, et al.International, multi-center, randomized, controlled study comparing dynamically individual-ized versus standard treatment in patients with chronic hepatitis C[J].J Hepatol, 2005, 43 (2) :250-257.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (3361) PDF downloads(805) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return